text:
The literature review was undertaken at Tufts Cummings School of Veterinary Medicine. No primary research was conducted. The summarized data have not appeared at any meeting.
Portal Hypertension: Pathophysiology, Diagnosis, and Treatment
Version of Record online: 7 MAR 2011
DOI: 10.1111/j.1939-1676.2011.00691.x
Copyright © 2011 by the American College of Veterinary Internal Medicine
Journal of Veterinary Internal Medicine
Volume 25, Issue 2, pages 169–186, March/April 2011
Additional Information
How to Cite
Buob, S., Johnston, A.N. and Webster, C.R.L. (2011), Portal Hypertension: Pathophysiology, Diagnosis, and Treatment. Journal of Veterinary Internal Medicine, 25: 169–186. doi: 10.1111/j.1939-1676.2011.00691.x
Publication History
- Issue online: 7 MAR 2011
- Version of Record online: 7 MAR 2011
- Submitted August 2, 2010; Revised October 27, 2010; Accepted January 6, 2011.
- Abstract
- Article
- References
- Cited By
- Ascites;
- Cirrhosis;
- Hepatic disease;
- Portosystemic shunts
- Top of page
- Abstract
- Anatomy and Physiology of Hepatic Blood Flow
- Classification of PH
- Pathophysiology of PH
- Consequences of PH
- Diagnostic Evaluation of PH
- Clinical Differentiation of Pre-, Post-, and Intrahepatic PH ()
- Treatment of PH
- Conclusion
- Footnotes
- Acknowledgment
- References
Portal hypertension (PH) is the result of increased vascular resistance in the portal circulation, increased portal venous blood flow, or both. In veterinary medicine, where portal pressure is seldom measured directly, the diagnosis of PH often is inferred from identification of associated complications including multiple acquired portosystemic shunts, ascites, and hepatic encephalopathy. Likewise, treatment of PH primarily is aimed at controlling these complications. The goal of this review is to provide an update on the pathophysiology, diagnosis, and treatment of PH. The review draws from information in the veterinary hepatology literature, reviews, and consensus statements in human hepatology and the literature on experimental models of PH.
antidiuretic hormone
congenital portosystemic shunts
contrast-enhanced helical computed tomography
free hepatic venous pressure
hepatic encephalopathy
hepatic venous portal pressure gradient
intrahepatic venous resistance
multiple acquired portosystemic shunts
noncirrhotic portal hypertension
nitric oxide
nitric oxide synthase
portal blood flow
portal hypertension
primary hypoplasia of the portal vein
portal vein pressure
sinusoidal endothelial cell
wedged hepatic venous pressure
Portal hypertension (PH) is caused by increased resistance, increased blood flow, or both in the portal circulation. The clinical consequences of PH, which include the development of multiple acquired portosystemic shunts (MAPSS), ascites, hepatic encephalopathy (HE), or some combination of these, cause significant morbidity and mortality.1–3 Reviews of PH appeared in the veterinary literature in the 1980s, which the interested reader is encouraged to consult.4–6
Anatomy and Physiology of Hepatic Blood Flow
- Top of page
- Abstract
- Anatomy and Physiology of Hepatic Blood Flow
- Classification of PH
- Pathophysiology of PH
- Consequences of PH
- Diagnostic Evaluation of PH
- Clinical Differentiation of Pre-, Post-, and Intrahepatic PH ()
- Treatment of PH
- Conclusion
- Footnotes
- Acknowledgment
- References
The liver receives approximately 25% of the cardiac output through a dual vascular supply. The portal venous circulation provides 75–80% of the blood supply through a low pressure system.6–8 The hepatic artery delivers the rest of the blood supply.9 Blood from the portal vein and hepatic artery enter the hepatic lobule at the portal triad and mix together in the hepatic sinusoids (Fig 1). Because sinusoidal endothelial cells (SEC) have large fenestrae and lack a basement membrane, the sinusoids are considered a "leaky" capillary bed. After passing through the hepatic cords, sinusoidal blood drains into the hepatic central vein and then out of the liver through the hepatic veins, eventually reaching the caudal vena cava for return to the right atrium (Fig 1).
In accordance with Ohm's law: P (pressure) =Q (blood flow) ×R (resistance), portal vein pressure (PVP) is equal to the product of portal blood flow (PBF) and the resistance to that flow (intrahepatic venous resistance [IHVR]): PVP = PBF × IHVR.4,10–13 The PVP can be measured directly or indirectly. Direct measurement is obtained by catheterization of the portal vein or one of its tributaries and insertion of a manometer (cmH2O) or pressure transducer (mmHg). A considerable body of data exists on the direct measurement of PVP in dogs and cats in both the experimental literature and in reports on surgical attenuation of congenital portosystemic shunts (CPSS).4,5,14–42 In experimental studies in healthy, anesthetized dogs, PVP averages 8.24 ± 0.72 mmHg (multiply by 1.36 to convert to cmH2O), with a mean of 5.98 ± 1.99 mmHg in clinical reports. In experimental studies in anesthetized cats, PVP is 8.9 ± 0.35 mmHg with a mean of 7.38 ± 2.7 mmHg in the literature on portosystemic shunts. The variability in normal PVP reflects the effects of different anesthetic protocols as well as lack of standardization of the baseline zero value, which can be set at the right atrium, liver hilus, or vena cava.
In humans, indirect measurement of PVP is obtained by angiographic balloon catherization.43 A balloon-tipped catheter is inserted into the jugular or femoral vein and advanced with fluoroscopic guidance into the hepatic vein where measurement of the free hepatic vein pressure (FHVP) is taken (Fig 1). This measurement approximates pressure in the caudal vena cava. The balloon is inflated to occlude the hepatic vein, and the wedged hepatic vein pressure (WHVP) is measured. The WHVP is equivalent to sinusoidal pressure, which approximates PVP. A slight pressure gradient exists between the sinusoids (WHVP) and the caudal vena cava and hepatic vein (FHVP). This difference (WHVP−FHVP), the so-called hepatic venous pressure gradient (HVPG), provides the driving force for hepatopedal blood flow.10–13,43
Normal values for HVPG in humans are between 1 and 5 mmHg. Limited data in the dog and cat suggest that normal HVPG values are similar to those reported in humans.16,43,44 The normal FHVP and WHVP reported in a series of 11 normal dogs was 1.9 ± 1.0 and 5.6 ± 1.2 mmHg, respectively, resulting in a HVPG of 3.7 ± 1.4 mmHg.16 In a limited number of cats, FHVP and WHVP were reported as 1.5 ± 0.7 and 6.9 ± 1.7 mmHg, respectively, with a calculated HVPG of 5.4 mmHg.16 In humans, increases (>12 mmHg) in HVPG directly correlate with the clinical consequences of PH in cirrhotic patients.10–13,43 In addition, the success of treatment for PH is defined either by a >20% decrease in HVPG or reduction to <12 mmHg.10–13,43
Indirect measurement of PVP also can be obtained by catheterization of the splenic pulp. Normal splenic pulp values in veterinary patients appear to be 0.5–1.5 mmHg greater than those obtained by direct measurement.16
As direct or indirect measurement of PVP seldom is performed in veterinary medicine, the presence of PH most often is inferred by detection of late-stage clinical consequences (eg, ascites, MAPSS, HE) on physical examination or imaging studies or by assessment of portal vein hemodynamics with Doppler ultrasound.45
In the normal liver, PVP is remarkably stable despite changes in PBF.10–13 A large sinusoidal reserve and adaptive responses in the intrahepatic vasculature contribute to a compliant vascular bed that can increase its volume considerably to accommodate additional PBF without changes in pressure. Increased PBF stimulates SEC's to release nitric oxide (NO), which dilates intrahepatic vessels to accommodate a larger blood volume.10–13
Several factors cause minor fluctuations in the PVP. Lower PVP occurs during anesthesia, inspiration, fasting, and exercise. Transient increases develop postprandially, during expiration, by increases in intra-abdominal pressure (such as during barking or defecation), after blood volume expansion and after the injection of angiographic agents.4,15,46
Classification of PH
- Top of page
- Abstract
- Anatomy and Physiology of Hepatic Blood Flow
- Classification of PH
- Pathophysiology of PH
- Consequences of PH
- Diagnostic Evaluation of PH
- Clinical Differentiation of Pre-, Post-, and Intrahepatic PH ()
- Treatment of PH
- Conclusion
- Footnotes
- Acknowledgment
- References
PH is classified based on anatomical location as prehepatic, intrahepatic, or posthepatic (Table 1).4,10–13 Prehepatic PH is because of increased resistance in the extrahepatic portal vein and is associated with mural or intraluminal obstruction (eg, congenital atresia or fibrosis, thrombosis, neoplasia) or extraluminal compression.4,5,8,47–52 Hepatic arteriovenous fistulas cause prehepatic PH as arterial blood floods the portal venous system.8,53–55 These fistulas usually are congenital, but may develop secondary to surgery, trauma, or neoplastic vascular erosion. Prehepatic PH also may occur as a complication of CPSS attenuation.7
|Prehepatic (Portal Vein)
|Intrahepatic (Liver)
|Posthepatic (Heart, CVC, Hepatic Veins)
|Congenital portal vein atresia Intraluminal obstruction Thrombus Neoplasia Stenosis Extraluminal obstruction Neoplasia Lymph node Granuloma Abscess
|Presinusoidal Primary hypoplasia portal vein (noncirrhotic portal hypertension) Chronic cholangitis Hepatic arteriovenous fistula Schistosomiasis Nodular hyperplasia Ductal plate abnormalities (Caroli's disease) Sinusoidal Cirrhosis/chronic hepatitis Chronic cholangiohepatitis Ductal plate abnormalities (Congenital hepatic fibrosis) Lobular dissecting hepatitis Postsinusoidal Veno-occlusive disease (Sinusoidal obstruction syndrome)
|Right heart failure Congestive Pericardial tamponade Constrictive pericarditis Intracardiac neoplasia Congenital cor triatriatum CVC/hepatic vein obstruction (Budd-Chiari syndrome) Intraluminal Thrombosis Vena cava syndrome Neoplasia Extraluminal Neoplasia Kinking of CVC
Intrahepatic PH is because of increased resistance in the microscopic portal vein tributaries, sinusoids, or small hepatic veins. Intrahepatic PH is further classified by histological criteria into presinusoidal, sinusoidal, and postsinusoidal PH (Table 1, Fig 1). Presinusoidal PH occurs because of increased resistance in the terminal intrahepatic portal vein tributaries.48,51,56–63 In humans, the most common cause is noncirrhotic portal hypertension (NCPH) (also called hepatoportal sclerosis and idiopathic portal hypertension).56 Similar clinical syndromes called NCPH, primary hypoplasia of the portal vein (PHPV), idiopathic hepatic fibrosis, and hepatoportal fibrosis have been reported in dogs.57–64 Fibropolycystic liver disorders, such as congenital hepatic fibrosis and Caroli's disease, also can cause presinusoidal PH in dogs and cats.64–68 These developmental disorders because of the persistence of embryonic duct structures are referred to as ductal plate malformations. They lead to varying degrees of bile duct pathology and portal fibrosis. When the latter is severe, PH can occur. A rare cause of prehepatic PH occurs in dogs with trematode infestations (Schistosoma japonicum and Heterobilharzia americana).8,69 Increased resistance to flow is because of granulomatous inflammation in the portal veins triggered by trematode eggs.
Sinusoidal intrahepatic PH most often is the result of fibrotic hepatopathies.70,71 In these disorders, SEC's lose their fenestrae and acquire a collagenous basement membrane (capillarization of the sinusoids) increasing IHVR. In addition, lobular fibrosis and the presence of regenerative nodules contribute to the obliteration and distortion of the sinusoids further increasing IHVR. Although not typical, canine nodular hyperplasia, a common idiopathic lesion in old dogs, also may distort the sinusoids leading to PH.58,72,73
Postsinudoidal intrahepatic PH is associated with veno-occlusive disease (also called sinusoidal obstruction syndrome). Veno-occlusive disease is caused by damage to the sinusoidal endothelium and hepatocytes in the centrilobular region, resulting in obliteration of the small terminal hepatic veins and central veins by fibrosis. It has been associated with toxins, graft-versus-host disease and chemotherapy agents in humans, and been reported as an idiopathic condition in veterinary patients.74–78
Posthepatic PH is associated with obstruction of the larger hepatic veins, the posthepatic caudal vena cava, or right atrium. Obstruction at the right atrium because of right heart failure, pericardial disease, or pulmonary hypertension is a common reason for posthepatic PH in small animals.79–81 When obstruction occurs in the hepatic venous outflow in the caudal vena cava or larger extrahepatic hepatic veins, it is known as Budd-Chiari syndrome.74 Budd-Chiari syndrome most often is because of intraluminal (tumor, thrombosis, congenital fibrous webs) or extraluminal (tumor) compression.44,82–89
Classification of the site of PH has clinical relevance because the level of obstruction often dictates the clinical presentation (ie, whether MAPSS, ascites, or HE develops), diagnostic evaluation (increases in liver enzyme activities, protein content of ascitic fluid, type of diagnostic imaging), and treatment (Table 2). The impact of PH classification on these variables is discussed next.
|Physical Exam
|Laboratory Values
|Liver Biopsy: Histopathology
|Prehepatic (PVP-, FHVP-N, WHVP-N, HVPG-N)
|PV atresia
|Young with ascites, HE
|LE: N to mild Ascites: pure transudate
|Chronic hypoperfusion
|PV obstruction
|Acute onset, abdominal pain, ascites
|Normal or abnormal with concurrent hepatic disorder
|Intrahepatic Presinusoidal (PVP-, FHVP-N, WHVP-N, HVPG-N)
|Hepatic arteriovenous fistula
|Young with ascites, HE, bruit
|LE: N to mild Ascites: low-protein transudate
|Chronic hypoperfusion
|Primary hypoplasia of the portal vein/noncirrhotic portal hypertension
|Young adult with ascites, GI signs, HE, ± icterus
|LE: moderate Coagulopathy ±bilirubin Ascites: low-protein transudate
|Chronic hypoperfusion ± periportal fibrosis; no inflammation or nodular hyperplasia
|Ductal plate abnormalities (Caroli's syndrome)
|Young with ascites, GI signs, PU/PD
|LE: moderate Ascites: low-protein transudate
|Numerous irregular bile ducts localized along the edge of limiting plate, portal fibrosis, no inflammation, or regenerative nodules ± renal cysts
|Sinusoidal (PVP-, FHVP-N, WHVP-, HVPG-)
|Ascites, HE, GI signs, PU/PD ± icterus, Breed predilections
|LE: mild to marked ± serum bilirubin Coagulopathy Ascites: pure or modified transudatea
|Inflammation/necrosis/apoptosis, fibrosis, ± regenerative nodules
|Lobular dissecting hepatitis
|Young to middle age dog, ascites HE, GI signs ± icteric
|Parenchymal inflammation, infiltration of lobular reticulin and collagen fibers
|Ductal plate abnormalities (congenital hepatic fibrosis)
|Young with ascites, HE, GI signs
|As in Caroli's above, but extensive panlobular fibrosis, mild degree of portal vasculature hypoplasia and arteriolar proliferation ± renal cysts/fibrosis
|Postsinusoidal (PVP-, FHVP-, WHVP-, ± HVPG-)
|Veno-occlusive disease (sinusoidal obstruction syndrome)
|Ascites, HE, GI signs,
|LE: N toa mild Ascites: high protein modified transudate
|± Centrilobular fibrosis, intra/extraluminal HV compression, ± thrombosis, ± dilated centrilobular lymphatics/vasculature
|Posthepatic (PVP-, FHVP-, WHVP-)
|Cardiac (CVP, HVPG-N)
|Ascites, edema, jugular distension, murmur, arrhythmia
|LE: N to mild Ascites: high protein modified transudate
|Hepatic congestion, dilated centrilobular lymphatics/vasculature
|Budd-Chiari (CVC or HV) (± HVPG-)
Pathophysiology of PH
- Top of page
- Abstract
- Anatomy and Physiology of Hepatic Blood Flow
- Classification of PH
- Pathophysiology of PH
- Consequences of PH
- Diagnostic Evaluation of PH
- Clinical Differentiation of Pre-, Post-, and Intrahepatic PH ()
- Treatment of PH
- Conclusion
- Footnotes
- Acknowledgment
- References
PH secondary to prehepatic or posthepatic obstructive, stenotic, or constrictive vascular lesions develops primarily because of increased resistance to flow in the vessels in accordance with Ohm's law. The pathophysiologic mechanisms controlling the development of intrahepatic sinusoidal PH are less intuitive and, despite extensive investigation, not fully understood. An important factor is mechanical obstruction secondary to architectural changes in the liver. These changes include fibrosis, capillarization of the sinusoids, presence of microthrombi in the intrahepatic vasculature, and regenerative nodule formation.10–13 In addition to mechanical obstruction, dynamic changes in sinusoidal tone contribute to increased IHVR (Fig 2).10–12 The SECs normally produce vasoactive substances that regulate sinusoidal resistance. These include vasodilatory substances such as NO, carbon monoxide, and prostaglandin E2, and vasoconstrictors such as endothelin-1, angiotensin II, leukotrienes, and norepinephrine. In the diseased liver, overproduction of inflammatory mediators and the resultant oxidative stress cause SEC dysfunction, which leads to overproduction and enhanced sensitivity to vasoconstrictors and underproduction of vasodilators. The net result is impaired sinusoidal relaxation.
Vascular NO, the most important vasodilator in the liver, is synthesized in reactions catalyzed by 1 of 2 isoforms of nitric oxide synthase (NOS): endothelial NOS, which stimulates endothelial cell production of NO in response to physical stimuli such as shear stress, and inducible NOS, which is induced by proinflammatory cytokines.10,11,90 The intrahepatic NO deficiency seen with PH is due primarily to decreased activation of endothelial NOS.10–13,90,91
Activation of hepatic stellate cells, which in the unstimulated state are quiescent lipid-storing cells surrounding the sinusoids, also contributes to increased IHVR. During injury, stellate cells differentiate into contractile, fibrogenic myofibroblasts, which produce large amounts of extracellular matrix and secrete inflammatory cytokines and vasoconstrictive substances such as endothelin-1. These vasoconstrictors act in an autocrine fashion to stimulate stellate cell contraction, which reduces the diameter of the sinusoidal space and increases IHVR.11,12,90
Unlike the vasoconstriction seen in the intrahepatic vasculature during PH, the splanchnic vasculature undergoes progressive vasodilatation because of an excess of vasodilatory substances, particularly NO.11,90,91 The mechanisms responsible for the overproduction of NO include increased vascular shear stress and intestinal absorption of lipopolysaccharide. Increased sheer stress activates endothelial NOS. Increased intestinal absorption of lipopolysaccharide secondary to the changes in intestinal permeability that accompany PH stimulates the release of inflammatory cytokines such as tumor necrosis factor-α from the macrophages, which enhances the activity of inducible NOS.90–92 Other substances that contribute to peripheral vasodilatation include hydrogen sulfide, carbon monoxide, prostaglandins, and endocannabinoids.11,90 The combined action of the all these vasodilatory compounds mediates progressive and sustained vasodilatation of the splanchnic circulation leading to higher PBF, which maintains and aggravates the development of PH (Fig 2).
Recent studies suggest that angiogenesis also contributes to the establishment and maintenance of PH.11,92 The development of fibrotic septa and capillarization of the hepatic sinusoids results in relative hepatic hypoxia stimulating the release of angiogenic factors from hepatic stellate cells and SEC. These factors, particularly vascular endothelial growth factor and platelet-derived growth factor, stimulate angiogenesis fueling higher PBF and worsening PH.
Consequences of PH
- Top of page
- Abstract
- Anatomy and Physiology of Hepatic Blood Flow
- Classification of PH
- Pathophysiology of PH
- Consequences of PH
- Diagnostic Evaluation of PH
- Clinical Differentiation of Pre-, Post-, and Intrahepatic PH ()
- Treatment of PH
- Conclusion
- Footnotes
- Acknowledgment
- References
Ascites occurs as a consequence of imbalances in Starling's law so that the forces keeping fluid in the vascular space are less than the forces moving fluid out of the vascular space.12,13,93,94 In PH, increased PVP drives fluid into the interstitial space. When the capacity of the regional lymphatics is overwhelmed, ascites develops. The development of ascites is perpetuated by the splanchnic vasodilatation that accompanies PH. This vasodilatation results in pooling of blood in the abdomen, which leads to a decrease in effective systemic blood volume (Fig 2). Initially, increased cardiac output is compensatory, establishing the hyperdynamic circulation of hepatic disease marked by high cardiac output and low systemic vascular resistance.90–94 As liver disease progresses, vasodilators that escape hepatic degradation accumulate in the systemic circulation and systemic arteriolar vasodilatation worsens (Fig 2). Eventually, inotropic and chronotropic compensation fails, and systemic hypotension ensues. This results in activation of the endogenous vasopressor system, including the renin-angiotensin-aldosterone system, sympathetic neurons, and the nonosmotic release of antidiuretic hormone (ADH). Resultant volume expansion further increases hydrostatic pressure in the portal vasculature causing increased lymph formation.93,94 Concurrent hypoalbuminemia secondary to hepatic synthetic failure lowers vascular colloid osmotic pressure that furthers aggravates ascites formation.94 The presence of ascites is a negative prognostic factor in dogs with chronic hepatitis.1
Acquired Portosystemic Shunts
As the HVPG increases above 12 mmHg, MAPSS develop from the opening of embryonic vessels between the portal vasculature and the cranial and caudal vena cava. Initially, blood flow through MAPSS may lower PVP, but parallel increases in PBF because of splanchnic vasodilatation eventually restore PH. In experimental canine models of PH, MAPPS form over a period of 5–14 weeks.95,96 Although MAPSS form primarily because of pressure gradients, there also is evidence that angiogenic factors contribute to their formation and maintenance.92 All forms of PH can be accompanied by MAPSS with the exception being posthepatic PH in which no pressure gradient exists between the portal and systemic circulation (ie, HVPG is normal, Table 2).
Acquired shunts are classified based on anatomic location. Portal precaval shunts connect the portal vein with the caudal vena cava either directly or by way of the azygous vein, whereas portal postcaval shunts connect the portal vasculature to the cranial vena cava. In humans, a common site for precaval MAPSS is between the portal vein and submucosal esophageal vessels.97 These shunts, called esophageal varices, are prone to rupture and bleeding and are an important cause of morbidity in humans with PH. Esophageal varices form in the dog and cat, but are rarely of clinical relevance.98–100 Most MAPSS in small animals are portal postcaval shunts. In dogs, large velar-omental shunts arise from the splenic vein, anastomose with embryonic connections to the left gonadal veins and empty into the left renal vein and ultimately the caudal vena cava.4,5,8,100 In dogs, smaller portal collateral vessels develop and are classified by their location and drainage patterns as left gastric, gastrophrenic, omental, gallbladder, abdominal wall duodenal, and colic varices.4,5,100 Cats tend to develop shunts between the left gastric veins and phrenicoabdominal veins and from the left colic vein to the left gonadal vein.4,5,8
HE is a syndrome of neurocognitive impairment that clinically is manifested as a range of signs from subtle behavioral deficits to stupor and coma.101–103 The pathogenesis is multifactorial, and associated with toxins derived from the gastrointestinal tract that bypass hepatic metabolism. Ammonia derived primarily from the action of colonic bacterial on the breakdown products of ingested protein is one of the most important toxins. Ammonia, which normally is transported to the liver via the portal circulation where it is metabolized in the urea cycle, directly enters the systemic circulation through MAPSS. The excess blood ammonia penetrates the blood brain barrier and causes neuronal dysfunction by incompletely understood mechanisms. Current evidence supports a central role of ammonia-induced astrocyte dysfunction.101–103 Astrocytes, which are the only cells in the brain that express glutamine synthetase, detoxify brain ammonia with this enzyme to catalyze the conversion of glutamate to glutamine. The intracytoplasmic accumulation of osmotically active glutamine results in low-grade astrocyte swelling and subsequent induction of signaling pathways that lead to the formation of reactive oxygen species. This results in astrocyte dysfunction and altered neurotransmission.103
The same forces that promote ascites formation can lead to development of dilutional (hypervolemic) hyponatremia.93,104 Nonosmotic release of ADH, in response to decreased effective blood volume secondary to peripheral vasodilatation, acts on water channels in the renal tubules to promote water retention. This action eventually leads to a deficit in free water excretion and results in hyponatremia. In human patients with cirrhosis, the development of hyponatremia is a marker of late stage disease and a negative prognostic indicator.93,104
Hepatorenal Syndrome
Another consequence of the hyperdynamic circulatory derangements associated with PH is hepatorenal syndrome. This syndrome, a form of reversible renal failure, occurs as a consequence of profound renal vasoconstriction secondary to the release of angiotensin, norepinephrine, and ADH in response to splanchnic vasodilatation.105,106 Although hepatorenal syndrome can be induced in experimental canine models,107,108 it has not been reported clinically in veterinary patients. In humans, the syndrome is always accompanied by a state of refractory ascites and end-stage liver failure.11–13,105,106
Hepatopulmonary Syndrome, Portopulmonary Syndrome, and Hepatic Hydrothorax
Hepatopulmonary syndrome, portopulmonary hypertension, and hepatic hydrothorax are pulmonary complications of PH in humans that have not been reported in veterinary medicine.109–112 Hepatopulmonary syndrome occurs because of microvascular pulmonary arterial dilatation (most likely because of NO overproduction in the lung) leading to ventilation-perfusion mismatch.109–111 Portopulmonary hypertension is likely mediated by humoral substances that enter the systemic circulation through MAPSS.110,112 Initially, these substances cause vasoconstriction, but subsequent thrombosis leads to vessel obliteration. Hepatic hydrothorax is the presence of pleural effusion in patients with hepatobiliary disease. It likely arises because of direct passage of ascites from the abdomen to the thorax through undetectable diaphragmatic rents.111
Spontaneous Bacterial Peritonitis
Spontaneous bacterial peritonitis is infection of ascitic fluid without a detectable nidus.113,114 It occurs in 8–30% of hospitalized cirrhotic human patients with ascites, with an associated mortality of 20–40% if untreated.113 Many patients are asymptomatic, but clinical signs can include abdominal pain, fever, and diarrhea. A neutrophil count >250 cells/mm3 in the ascitic fluid is diagnostic, regardless of whether or not organisms are visible cytologically. The pathophysiology of spontaneous bacterial peritonitis is incompletely understood but 4 key components are involved: (1) the presence of small intestinal bacterial overgrowth, (2) increased intestinal permeability, (3) intestinal bacterial translocation, and (4) immunosuppression. Spontaneous bacterial peritonitis occurs in dogs and cats,115,116 but has not been reported in the setting of PH.
Splenomegaly is a rare finding in PH in dogs and cats,117 but is common in humans with PH and can lead to hypersplenism.10–13 Hypersplenism is associated with pooling of blood in the spleen, destruction of blood cells by the enlarged spleen, or both. The clinical consequence is pancytopenia. This syndrome has not been described in dogs or cats with PH, perhaps because of anatomic differences that prevent splenic congestion in these species.117
Portal Hypertensive Gastropathy
In humans, gastric mucosal lesions associated with portal hypertensive gastropathy are present in 51–98% of patients with PH.118 Histologically, this gastropathy is defined by mucosal and submucosal vascular ectasia in the absence of inflammation. Similar lesions can be found in the small and large bowel. Many factors including alterations in splanchnic blood flow, humoral factors, and local dysregulation of vascular tone have been implicated in the pathophysiology. In humans, portal hypertensive gastropathy increases the risk for acute and chronic gastrointestinal bleeding.118
Although the characteristic histologic lesion associated with portal hypertensive gastropathy has not been reported in veterinary patients, dogs and cats with hepatic disease are at increased risk for gastrointestinal ulceration.59,119,120 In humans with PH, impairment of gastric mucosal defense occurs and is associated with thrombosis of mesenteric vessels because of circulatory stasis, alterations in gastrointestinal motility, bacterial overgrowth because of lack of intestinal bile acids, and mucosal edema because of increases in gastrointestinal mucosal permeability. Overproduction of vasocontrictors such as endothelin-1, increased generation of free oxygen radicals, or both also have been implicated in the pathophysiology.
Diagnostic Evaluation of PH
- Top of page
- Abstract
- Anatomy and Physiology of Hepatic Blood Flow
- Classification of PH
- Pathophysiology of PH
- Consequences of PH
- Diagnostic Evaluation of PH
- Clinical Differentiation of Pre-, Post-, and Intrahepatic PH ()
- Treatment of PH
- Conclusion
- Footnotes
- Acknowledgment
- References
Clinical Pathology
CBC. Microcytosis is seen in dogs with MAPSS. It is not associated with iron deficiency, but rather with a currently unknown defect in mobilization of iron stores.121,122 Mild thrombocytopenia, anemia, or both maybe seen in some dogs with PH.59,123,124
Serum Liver Enzyme Activity. The magnitude of increases in serum liver enzyme activities is dependent on the underlying disorder causing PH. Typically, moderate to marked liver enzyme activity increases are associated with intrahepatic PH secondary to inflammatory or fibrotic hepatobiliary disorders. Disorders associated with posthepatic PH typically result in mild to moderate increases in serum enzyme activity, particularly the aminotransferases, because of hepatic necrosis or ischemia from congestion. Serum liver enzyme activities usually are normal or only mildly increased in prehepatic PH.
Liver Function Tests. Abnormal liver function tests can be used to infer the presence of PH. Blood ammonia or total serum bile acid concentrations can be increased in the presence of MAPSS or functional hepatic failure.125 Based on evidence in the literature on CPSS, postprandial total serum bile acid concentrations may be the most sensitive test for detection of MAPSS.126 Blood ammonia concentration, however, is more specific for MAPSS, reflecting the fact that total serum bile acid concentrations are more likely to be increased in cholestatic disorders.125,127 Ammonia is the only HE toxin that can be measured clinically, and documentation of hyperammonemia suggests the presence of HE (Table 3). Other clinicopathological indicators of hepatic dysfunction such as hyperbilirubinemia and decreases in serum albumin, urea nitrogen, and cholesterol concentrations may be seen in dogs or cats with intrahepatic sinusoidal PH (Table 2).
|Change with Portal Hypertension
|Measurement of portal vein pressurea
|Dog: >11 mmHg
|Cat: >12 mmHg
|Detection of MAPSS
|Decreased velocity of portal vein blood flow
|Hepatofugal flow in portal vein
|Portal vein/aortic <0.65 in the absence of single CPSS
|Detection of complications
|Ascites: Nonneoplastic, noninflammatory pure or modified transudate
|HE: Neurologic signs compatible with diffuse cerebral disease ± increased blood ammonia
|Gastrointestinal bleeding
Coagulation Parameters. Because the liver is responsible for the synthesis, activation, and clearance of both anti- and procoagulant factors, patients with hepatobiliary disease are in a precariously balanced state of coagulation.128 Spontaneous bleeding or thrombosis is rare, but when other predisposing factors such as infection, renal failure, endotoxemia, anesthesia, or drugs (eg, corticosteroids or nonsteroidal anti-inflammatory drugs) are present, they can tip the balance in favor of bleeding or thrombosis.128 In the literature available on the coagulation status of dogs with PH, the presence of prolonged bleeding times (prothrombin time and activated partial thromboplastin time) seems to parallel the extent of functional hepatic failure,48,123,124,129 and 2 studies in dogs have shown a relationship between prolongation of these parameters and survival.124,129 Other coagulation abnormalities that accompany hepatic disorders in dogs associated with PH are decreased serum concentrations of fibrinogen, antithrombin, and protein C.123,126 In cats (with their predilection to cholestatic biliary disorders), the most common coagulation abnormality reported is vitamin K-dependent prolongation of prothrombin time.130
Ascitic Fluid. In PH, the ascitic fluid typically is a pure or modified transudate (Table 3). The protein content of the fluid often reflects the anatomic location of PH. Prehepatic and presinusoidal PH increases intestinal lymph formation. Because the intestinal lymphatic system has a large absorptive capacity and tight capillary beds, the ascitic fluid has a low protein concentration (<2.5 g/dL). Posthepatic, postsinusoidal, and sinusoidal intrahepatic PH increase hepatic lymph formation, resulting in loss of a high protein fluid (>2.5 g/dL) through the leaky sinusoidal endothelium. However, because sinusoidal intrahepatic PH most often is accompanied by capillarization of the sinusoids and hepatic synthetic failure, the accumulating fluid typically has a low protein content.
Diagnostic Imaging
Radiography. The presence of ascites can be inferred on survey abdominal radiographs by loss of abdominal detail. Radiographic microhepatica or hepatomegaly may help confirm the presence of a hepatic disorder. Changes in thoracic radiographs, including cardiomegaly, prominent pulmonary vasculature, or compression or dilatation of the caudal vena cava, may indicate a posthepatic intrathoracic cause of PH.
Ultrasonography. Ultrasound examination of the abdomen is essential in the diagnostic appraisal of PH. Several findings can indicate the presence of PH (Table 2).131–136 First, ultrasonography can demonstrate the presence of even small amounts of ascites and aid in the acquisition of a diagnostic sample to determine if its composition is compatible with PH. Second, ultrasonography can identify the presence of MAPSS. Typically, MAPSS appear as a plexus of small, tortuous splenic to renal vessels in the left dorsal perirenal area.8,117,131,132 Large left splenogonadal shunts can be identified in some patients.100,117 MAPSS commonly run caudally from the site of origin and tend to disappear into the intestine. Multiple shunts can be differentiated from single congenital shunts by their greater number (>2), and smaller size (<0.4 cm).131 Postprandial increases in PBF may facilitate detection of MAPSS. Additional ultrasonographic findings suggestive of PH include an enlarged portal vein, decreased PBF velocity (<10 cm/s) hepatofugal flow, a dilated left gonadal vein, and a portal-vein-to-aorta ratio (PV/Ao) ≤ 0.65 (Table 3).100,117,131–135 In humans, ultrasonographic findings of increased PBF, decreased PBF velocity and increased congestive index (cross-sectional area of the PV/mean PV velocity) have 95% sensitivity and specificity for the identification of PH.45,136
Ultrasonographic evaluation of the hepatic parenchyma and biliary tract may help to anatomically localize the cause of PH. The liver may appear large and hypoechoic with congestion because of posthepatic PH or small with focal or diffuse parenchymal lesions in chronic hepatic disease leading to intrahepatic PH. Vascular anomalies such as intrahepatic hepatic arteriovenous fistulas and thrombosis in the portal vein can be identified. Evaluation of the biliary tree may show changes such as biliary tract dilatations, cysts, or mineralization that may be consistent with ductal plate abnormalities. Ultrasonographic evaluation of the heart and thorax can identify causes of posthepatic PH such as right heart failure, pericardial effusion, pulmonary hypertension, or intra- or extraluminal obstruction of the caudal vena cava.
Scintigraphy. Rectal or transplenic scintigraphy can confirm the presence of portosystemic hepatic bypass.137,138 Neither method, however, reliably defines the location of portosystemic bypass or differentiates between a single CPSS and MAPSS. Transplenic scintigraphy may enable visualization of a distinct plexus of multiple anomalous vessels in some, but not all patients.132
Angiography. Angiography is most useful for evaluating hepatic arteriovenous fistula and obstructive vascular causes of PH, which typically are pre- or posthepatic.45,86,138,139
Contrast-Enhanced Helical Computed Tomography (CT). Standard protocols for CT developed to evaluate the portal vasculature for CPSS in dogs, can be applied to the investigation of the portal vasculature in PH.100,140–142 The use of CT permits the identification of MAPSS, obstructive venous lesions, and hepatic arteriovenous fistula as well as determination of hemodynamic changes such as hepatofugal blood flow.142 A recent study provided a detailed description of patterns of MAPSS in veterinary patients with naturally occurring PH.100
Contrast-Enhanced Magnetic Resonance Angiography (MRA). MRA permits both accurate depiction of portal vascular anatomy and measurement of portal hemodynamics.143–146 Anatomical image quality is superior to CT for vascular assessment, but additional studies are needed to validate the method for use in disorders associated with PH.
Liver Histopathology
Histopathology is crucial in the evaluation of intrahepatic PH because it can differentiate among congenital, inflammatory, fibrotic, and vascular disorders. In inflammatory disorders, the distribution and type of infiltrating cells can be determined and the extent of both fibrosis and inflammation evaluated.8,124,147 Ductal plate abnormalities can be identified by typical patterns of bile duct proliferation and fibrosis. Diseases associated with chronic portal hypoperfusion of the liver such as hepatic arteriovenous fistula, NCPH, or portal vein obstruction, atresia or stenosis cause a stereotypical histological pattern in the liver that includes loss or diminution of the portal vasculature, arteriolar hyperplasia and tortuosity, hypertrophy of parenchymal hepatic arterioles, and hepatocellular atrophy.8 Biopsy changes with posthepatic syndromes such as veno-occlusive disease, Budd-Chiari syndrome, and cardiac failure can be subtle and difficult to differentiate. Changes occur predominantly in centrilobular or perivenular areas and include congestion within the space of Disse and centrilobular hepatocyte degeneration. With chronicity, fibrosis may appear in the sinusoids and centrilobular area eventually bridging between central veins.74 In prehepatic PH, histologic abnormalities may be absent unless the obstruction is longstanding in which case some degree of centrilobular hepatocyte degeneration can occur.
Clinical Differentiation of Pre-, Post-, and Intrahepatic PH (Table 2)
- Top of page
- Abstract
- Anatomy and Physiology of Hepatic Blood Flow
- Classification of PH
- Pathophysiology of PH
- Consequences of PH
- Diagnostic Evaluation of PH
- Clinical Differentiation of Pre-, Post-, and Intrahepatic PH ()
- Treatment of PH
- Conclusion
- Footnotes
- Acknowledgment
- References
Prehepatic causes of PH involve portal vein obstruction and hepatic arteriovenous fistula. Because some causes such as portal vein atresia and hepatic arteriovenous fistula are congenital lesions, the typical clinical presentation is a young animal with ascites and signs of HE.48–53 With portal vein obstruction, animals may present with abdominal pain and acute onset of ascites. Portal vein thrombosis often occurs in the presence of predisposing conditions such as chronic hepatitis, cirrhosis, pancreatitis, peritonitis, abdominal neoplasia, or endogenous or exogenous excess of corticosteroids.47,148–151 With prehepatic PH, serum liver enzyme activities typically are normal to mildly increased unless an underlying hepatopathy is present. Low protein ascites may be present. The diagnosis is made with ultrasound examination, CT, or contrast-enhanced MRA.
Posthepatic causes of PH involve the heart, cranial vena cava, and hepatic veins. Clinically, jugular venous distension, increased central venous pressure, cardiac murmur, high protein ascites, and hepatomegaly may be present.79–81 Hepatic congestion and subsequent ischemia cause mild to moderate increases in serum transaminase activities. Thoracic and abdominal ultrasonography or contrast angiography is needed for diagnosis.
Reports of presinusoidal intrahepatic PH, although not confirmed by manometry, have been described in dogs.48,51,57,59–63 In these reports, the syndrome has been called NCPH, hepatoportal scleral fibrosis, idiopathic hepatic fibrosis, and PHPV. The latter term is recommended by the World Small Animal Veterinary Association liver study group.8 It is unclear, however, if the lesion in all cases is primary hypoplasia of the intrahepatic portal vasculature or a consequence of a primary congenital or acquired disorder in hepatic perfusion. The pathogenesis of NCPH/PHPV in veterinary patients is unknown, but in humans NCPH is a vasculopathy involving the small and medium branches of the portal vein associated with exposure to toxins absorbed from the gastrointestinal tract (eg, lipopolysaccharide), autoimmune disorders, prothrombotic states, drugs or toxins (eg, methotrexate, arsenic, vinyl chloride), and hypervitaminosis A.59,152
Typically, dogs with NCPH/PHPV are young (<2 years of age), with ascites, HE, and gastrointestinal signs. Rottweilers, Cocker Spaniels, and Doberman Pinschers may be predisposed.51,57–59,62,63 Dogs have moderate to severe increases in liver enzyme activities, mild to moderate hyperbilirubinemia, increased total serum bile acids and blood ammonia concentrations, hypoalbuminemia, and a low protein ascitic fluid. Imaging studies show microhepatica with MAPSS. It may be impossible to differentiate this disorder from intrahepatic sinusoidal PH caused by inflammatory or fibrotic disease on the basis of clinical presentation, biochemical testing, and imaging findings. Instead, hepatic biopsy is necessary. In NCPH/PHPV, the liver has lesions associated with chronic hypoperfusion with varying degrees of periportal or centrilobular fibrosis. Noteworthy is the absence of inflammation and regenerative nodules. Supportive treatment has resulted in extended long-term survival in some dogs. Dogs with this syndrome appear to be predisposed to gastric ulceration.48,59,63
Postsinusoidal intrahepatic PH is caused by diseases affecting the small sublobular hepatic veins and central veins. It can occur as an idiopathic lesion in young, primarily large breed, dogs. German Shepherds appear to be overrepresented in these reports.61,63,78,145 Clinically and biochemically, they can be difficult to differentiate from dogs with NCPH/PHPV. Histopathologically, the liver has moderate to marked noninflammatory perivenular fibrosis, but not the classic signs of hypoperfusion seen with NCPH/PHPV. There are reports of extended survival in some of these dogs with symptomatic management. Whether some affected dogs represent overlap with NCPH/PHPV requires additional study.
Sinusoidal PH most often is associated with fibrosis in the sinusoids and accompanies chronic hepatitis or cirrhosis. Several breed-specific hepatopathies marked by copper- and noncopper-associated chronic hepatitis are known to progress to cirrhosis with development of PH.8,70,71 These diseases are seen in the Bedlington Terrier, West Highland White Terrier, Dalmatian, Doberman Pinscher, Cocker Spaniel, and Labrador Retriever.71 Another inflammatory disorder that culminates in PH in dogs is lobular dissecting hepatitis, a disorder reported primarily in young large breed dogs.153–155 Histologically, it is marked by a mixed inflammatory infiltrate in the sinusoids and hepatic parenchyma with rare involvement of portal areas. The lobular parenchyma is infiltrated by fine reticulin and collagen fibers. Regenerative nodules may be present but are not a prominent feature. The cause is unknown and response to supportive treatment is poor with most dogs dying within a few weeks of diagnosis.
Fibropolycystic hepatobiliary disease (ductal plate abnormalities) can cause either sinusoidal or presinusoidal PH. When the ductal plate abnormality is associated with small bile ducts (eg, congenital hepatic fibrosis), diffuse fibrosis and sinusoidal PH occur.64,68 Ductal abnormalities in larger bile ducts (Caroli's disease) may be associated primarily with portal fibrosis and result in presinusoidal PH.65,156 Histologically, the fibropolycystic diseases are characterized by the presence of numerous irregular bile duct profiles localized along the edge of the limiting plate with extensive, portal fibrosis. Inflammation and regenerative nodules are absent. In congenital hepatic fibrosis, dogs may have some degree of hypoplastic portal vasculature on biopsy with mild arteriolar proliferation. Thus, it may be difficult to differentiate congenital hepatic fibrosis from NCPH/PHPV, but the latter lacks profound changes in the bile ducts.64 Dogs with Caroli's disease typically have imaging abnormalities of the larger bile ducts, including dilatation and associated calcification, and have many concurrent renal cysts on ultrasound examination.65,156
PH and ascites formation occurs in cats with posthepatic PH (eg, right heart failure, Budd-Chiari syndrome), intrahepatic disease (eg, HAV, chronic hepatitis, congenital hepatic fibrosis), or prehepatic PH (eg, portal vein thrombus, postattenuation of CPSS).42,55,68,84,150,157–159 PH, however, is not as common in cats with inflammatory biliary disease.160,161 This may be related to the fact that feline cholangitis initally is marked by periductual fibrosis, but only in later stages does fibrosis progress to the hepatic architectural distortion or perisinusoidal fibrosis typically associated with development of PH in other species.161 Alternatively, cats may succumb to complications of hepatic failure before an advanced stage marked by ascites develops.159,162–165
Treatment of PH
- Top of page
- Abstract
- Anatomy and Physiology of Hepatic Blood Flow
- Classification of PH
- Pathophysiology of PH
- Consequences of PH
- Diagnostic Evaluation of PH
- Clinical Differentiation of Pre-, Post-, and Intrahepatic PH ()
- Treatment of PH
- Conclusion
- Footnotes
- Acknowledgment
- References
Correct Etiologic Factors
Treatment of PH ideally is based on correction of the underlying disease. This often is possible for PH associated with right-sided heart failure (after- and preload reduction), pre- or posthepatic thrombotic or obstructive vascular lesions (placement of stents,86 surgical embolectomy, use of thrombolytics, and anticoagulants), or HAV (liver lobectomy, ligation of the nutrient artery, fluoroscopically guided glue embolization of the fistula).7,53 Although specific therapies to directly lower PH accompanying intrahepatic PH are used in humans, their use has not been explored in veterinary patients. Thus, treatment is centered on management of complications and control of factors that potentiate PH. Potentiating factors that may exacerbate PH are fluid overload, excessive sodium intake and increased intra-abdominal pressure. Thus, judicious use of low sodium fluids, rest, fasting, dietary sodium restriction, and sedation is indicated.
Manage Complications
Ascites. Mobilization of ascites requires establishment of natriuresis. Sodium restriction is the initial therapeutic step. A diet that delivers <0.05 g/100 kcal of sodium is initiated. Diuretics are added if there is no response to sodium restriction. The diuretic of choice is the aldosterone antagonist, spironolactone, which acts in the renal collecting ducts to increase sodium excretion and conserve potassium. Spironolactone works slowly to mobilize fluid, and in humans, a response may take up to 14 days.94,102,166 The initial dosage is 1–2 mg/kg/d, which may be increased gradually over 3–5 day cycles. Low dose furosemide (0.5–1 mg/kg/d) facilitates establishment of natriuresis. Daily weight and abdominal girth assessments should be performed and hematocrit as well as serum creatinine and electrolyte concentrations monitored. A safe rate of diuresis extrapolated from human medicine is 0.5% of body weight daily.166 Diuretic dosage is tapered to the lowest effective dosage with maintenance on spironolactone alone. Diuretics should be discontinued or re-evaluated when hyponatremia, hypokalemia, azotemia, or worsening signs of HE occur.8,166
Abdominal paracentesis may be necessary initially or intermittently if tense ascites is present. Benefits include improvements in renal blood flow, splanchnic venous return, and respirations. Typically, 20–50% of the ascitic volume may be removed without incident, but circulatory collapse or decreased renal function can occur when removing large fluid volumes.94,166 In humans, treatment pre- or postparacentesis with human albumin or colloids IV is used when total volume paracentesis is performed to prevent alterations in renal function.94,166
Refractory ascites may necessitate greater dietary sodium restriction, total volume paracentesis, or the use of experimental therapies. Intravenous infusion of human or canine albumin to enhance intravascular colloid concentration may be attempted in acutely decompensating patients.166 In humans, transjugular intrahepatic portosystemic shunts are created.166 This technically challenging procedure lowers PVP by creating a direct intrahepatic pathway between the hepatic and portal veins. This procedure has not been used in veterinary patients, but surgical vena cava banding to attenuate MAPSS in dogs with experimentally induced hepatic failure has been reported.26 In this study, long-term survival and quality of life were similar in banded dogs and those treated medically, and thus the procedure was not recommended.
Hyponatremia. Aquaretics (tolvaptan and lixivaptan) bind to V2 receptors in the renal collecting ducts and antagonize the action of ADH, effectively blocking reabsorption of water.104 They are used in humans for the acute management of hyponatremia in a hospital setting. They have not been evaluated in veterinary patients.
HE. Modulation of intestinal production and absorption of toxins is the mainstay of HE treatment.102,167 Enteral administration of nonabsorbable disaccharides (eg, lactulose and lactitol) acidifies the colonic lumen, leading to conversion of NH3 to NH4+, which is membrane impermeable. Lactulose also provides a cathartic effect and limits intestinal bacterial ammonia production. Adverse effects of treatment include diarrhea, flatulence, and abdominal cramps. The initial dosage is 0.25–0.5 mL/kg PO q12h–q8h, but the dosage should be adjusted to achieve 2–3 soft stools per day. Lactulose enemas after a warm cleansing enema may be used as an emergency treatment for patients with severe HE. Lactitol (0.5–0.75 g/kg PO q12h) or lactulose powdera may be better tolerated or more easily administered in some patients.
Antibiotics frequently are used in combination with lactulose for a synergistic effect in treating HE.168 Antibiotics work in the gut to limit urease-producing bacteria. The antibiotics most commonly used are metronidazole and neomycin.102 Neomycin's adverse effects include nephrotoxicity and ototoxicity, whereas metronidazole may cause neurotoxicity. In human medicine, there is a shift toward the use of rifaximin, an oral rifamycin-based antibiotic, because of its superior safety profile.168 The use of rifaximin has not been described in veterinary medicine, but safety profiles have been completed in dogs.169
Dietary protein restriction decreases colonic ammonia production, but in order to avoid protein calorie malnutrition, it should not be first-line treatment to control HE. Protein tolerance should first be increased with lactulose and antibiotic therapy, and protein restriction initiated if these interventions do not control HE. The protein source used is crucial. Dairy and soy protein along with higher amounts of vegetable fiber are best tolerated.170,171
Correction of factors that might precipitate HE such as metabolic alkalosis, infection, increased protein load (eg, gastrointestinal bleeding, diet), azotemia, constipation, and concurrent administration of sedatives or analgesics should be addressed.
Gastropathy. Gastrointestinal ulceration accompanying hepatobiliary disease can be treated by gastric acid reduction with H2 receptor antagonists or proton pump inhibitors and use of gastric mucosal cytoprotective agents such as sucralfate. Hepatotoxicity because of H2 receptor antagonists occurs as a rare idiosyncratic drug reaction in humans, but has not been reported in veterinary patients.172
Target Vasoactive Regulatory Pathways (Table 4)
|Therapeutic Goal
|Mechanism of Action
|Clinical Use (Humans)
|Splanchnic vasocontriction
|Propranolol Nadolol Carvedilol
|Nonselective β-adrenergic antagonists
|Chronic maintenance to PVP
|Propranolol not effective in dogs Carvedilol also an α1 agonist
|Somatostatin analogue
|Acute PVP
|Parenteral only
|Vasopressin analogue
|Acute PVP
|Parenteral only
|Sinusoidal vasodilation (IHVR)
|Isosorbid 5- mononitrate Isosorbid –dinitrate
|Deliver NO to intrahepatic vasculature
|Use in combination with β blockers for chronic maintenance to PVP
|Worsens splanchnic vasodilation Symptomatic systemic hypotension
|Lovastatin Atrovastatin
|endothelial NOS
|Preclinical to PH additive effect with β blockers
|Cholesterol lowering Corrects endothelial cell dysfunction
|Angiotensin II receptor antagonist
|Preclinical to PH and portopulmonary hypertension
|Nonselective endothelin receptor antagonist
|Portopulmonary hypertension
|Splanchnic neovascular ization
|Tyrosine kinase inhibitor
|Preclinical to PH and portopulmonary hypertension
Induce Splanchnic Vasoconstriction (Reverse Splanchnic Vasodilatation).
β Blockers. Oral treatment with nonselective β blockers such as propanolol and nadolol is used in humans to lower PVP on a chronic basis.97 They reduce PVP by way of both β1 and β2 blockade, which decreases cardiac output and mediates splanchnic vasoconstriction, respectively. However, 3 experimental studies and 1 clinical study in dogs have failed to document any reduction in PVP with propranolol even at doses high enough to elicit systemic hypotension.173–175 Carvedilol, another nonselective β blocker, also lowers PVP in humans. It is 2–3 times more potent than propranolol as a β-receptor antagonist.176 It also has mild α-1 adrenergic activity, which decreases IHVR resulting in a further reduction in PVP, but also may be associated with systemic vasodilatation and hypotension. Carvedilol has antioxidant activity, which may benefit patients with inflammatory or fibrotic disease.176 Its use has not been reported in veterinary patients with PH.
Somatostatin and Analogues. Somatostatin can decrease PVP in humans without leading to systemic hypotension.97 Somatostatin inhibits the release of splanchnic vasodilators such as glucagon and has a direct splanchnic vasoconstrictor effect. Somatostatin analogues such as octerotide are used parenterally to acutely lower PVP during active variceal bleeding in humans. Octreotide has been used in dogs to treat glucagonomas and insulinomas, but its use for PH has not been reported.177–178
Vasopressin and Analogues. Vasopressin acting at V1 receptors is a potent splanchnic vasoconstrictor.97 Terlipressin, a synthetic ADH analog, often is used alone or in combination with a somatostatin analogue to acutely lower PVP in humans with variceal bleeding.97 Adverse effects include systemic hypertension, arrhythmias, and myocardial and intestinal ischemia. In 1 experimental study, vasopressin was able to decrease gastric mucosal ischemia in dogs with PH.174 Potential applications of combinations of ADH and somatostatin analogue therapy in veterinary medicine include PH associated with acute increases in PVP such as might occur after PVT or as a complication of CPSS ligation.
Induce Sinusoidal Vasodilatation (Decrease IHVR).
Drugs that Increase the Availability of NO. Nitrovasodilators (which increase intrahepatic NO) decrease IHVR, but often at the expense of potentiating splanchnic vasodilatation and systemic hypotension.97 Thus, these compounds are not used as sole treatment for PH. Chronic oral treatment with isosorbide 5-mononitrate, however, is frequently used in combination with nonselective β blockade as first-line treatment to treat PH in humans.97,179,180 Although pharmacokinetic data are available for the oral administration of isosorbide 5-mononitrate in dogs, its use in PH has not been described.171
The statins, best known for their cholesterol lowering effects, also decrease IHVR without any adverse effects on systemic hemodynamics.181–183 They work in part by selectively increasing NO production in the liver through enhancement of endothelial NOS activity. The use of statins to control PH has not been investigated in veterinary patients, although these drugs have been used to lower cholesterol and treat inflammatory skin disease.184,185 An important concern with the use of statins is the potential for inducing idiosyncratic hepatotoxicity. A number of studies in humans, however, have shown that the safety profile of statins in patients with liver disease is no different than that observed in the general population.186
Renin-Angiotensin System Blockade. Activation of the renin-angiotensin-aldosterone system system occurs with PH and contributes to excessive vascular tone in the liver. ACE inhibitors decrease HVPG in humans, but often cause systemic hypotension.187 Losartan, an angiotensin II receptor antagonist, decreases PVP without causing systemic hypotension.187 Losartan also corrects splanchnic and pulmonary vascular endothelial dysfunction by preventing upregulation of endothelial NOS and decreasing reactive oxidative stress. Chronic administration can decrease PVP in some, but not all, studies.187 Losartan also inhibits hepatic stellate cell activation and can attenuate hepatic fibrosis in experimental rodent models making it particularly attractive for the treatment of PH associated with chronic fibrotic hepatopathies. Losartan has been used experimentally in dogs, but not to treat PH.188,189
Inhibition of Angiogenesis. The tyrosine kinase inhibitors such as sorafenib and imatinib block growth factor pathways crucial to angiogenesis. In experimental models of PH in rodents, sorafenib decreases splanchnic neovascularization, markedly attenuates the hyperdynamic splanchnic and systemic circulation, and decreases in the formation of MAPSS.191,192 The successful use of imatinib to treat portopulmonary hypertension in cirrhotic patients also has been reported.193 Although tyrosine kinase inhibitors are used in veterinary oncology, their use in PH has not been described.194
- Top of page
- Abstract
- Anatomy and Physiology of Hepatic Blood Flow
- Classification of PH
- Pathophysiology of PH
- Consequences of PH
- Diagnostic Evaluation of PH
- Clinical Differentiation of Pre-, Post-, and Intrahepatic PH ()
- Treatment of PH
- Conclusion
- Footnotes
- Acknowledgment
- References
Definitive diagnosis and treatment of PH in dogs and cats is challenging. Diagnosis often is delayed because it must be inferred by late-stage clinical signs such as accompanying ascites or HE, or by the identification of MAPSS by imaging techniques. The treatment of veterinary patients with PH is primarily directed at controlling complications such ascites, HE, and gastric ulceration. In cases, in which these clinical syndromes are refractory to treatment, pharmacologic intervention to lower PVP may be indicated. Challenges in veterinary medicine are to further define the use of imaging techniques to enable early detection of PH and to conduct clinical trials of pharmacologic interventions that lower PVP in dogs and cats in order to assess their effect on survival and quality of life in patients with PH.
- Top of page
- Abstract
- Anatomy and Physiology of Hepatic Blood Flow
- Classification of PH
- Pathophysiology of PH
- Consequences of PH
- Diagnostic Evaluation of PH
- Clinical Differentiation of Pre-, Post-, and Intrahepatic PH ()
- Treatment of PH
- Conclusion
- Footnotes
- Acknowledgment
- References
a Kristalose (lactulose), Cumberland Pharmaceuticals Inc, Nashville, TN
- Top of page
- Abstract
- Anatomy and Physiology of Hepatic Blood Flow
- Classification of PH
- Pathophysiology of PH
- Consequences of PH
- Diagnostic Evaluation of PH
- Clinical Differentiation of Pre-, Post-, and Intrahepatic PH ()
- Treatment of PH
- Conclusion
- Footnotes
- Acknowledgment
- References
No grant support or other funding was received for this project.
- Top of page
- Abstract
- Anatomy and Physiology of Hepatic Blood Flow
- Classification of PH
- Pathophysiology of PH
- Consequences of PH
- Diagnostic Evaluation of PH
- Clinical Differentiation of Pre-, Post-, and Intrahepatic PH ()
- Treatment of PH
- Conclusion
- Footnotes
- Acknowledgment
- References
- 1Ascites is a negative prognostic indicator in chronic hepatitis in dogs. J Vet Intern Med 2009;23:63–66., , ,
- 2Diagnosis and prognosis of chronic hepatitis and cirrhosis in dogs. J Small Anim Pract 1995;36:521–528.
- 3Primary hepatitis in dogs: A retrospective review (2002–2006). J Vet Intern Med 2009;23:72–80., , , et al.
- 4Portal hypertension. Part I. Pathophysiology and clinical consequences. Compend Continuing Educ Pract Vet 1987;9:741–748.
- 5Portal hypertension. Part II. Clinical assessment and treatment. Compend Continuing Educ Pract Vet 1987;9:917–925.
- 6Management of portal hypertension and its consequences. Vet Clin North Am Small Anim Pract 1995;25:461–483.,
- 7Portosystemic vascular anomalies. Vet Clin North Am Small Anim Pract 2009;39:513–541.,
- 8RothuzienJ, BunchSE, CharlesJA, et al., eds. WSAVA Standards for Clinical and Histological Diagnosis of Canine and Feline Liver Diseases, 1st ed. Philadelphia, PA: WB Saunders Elsevier; 2006.
- 9Branching patterns of the hepatic artery in the dog; Arteriographic and anatomic study. Am J Vet Res 1980;41:1090–1097., ,
- 10The hyperdynamic circulation of chronic liver diseases: From patient to the molecule. Hepatology 2006;43:S121–S131.,
- 11Hepatic endothelial dysfunction and abnormal angiogenesis: New targets in the treatment of portal hypertension. J Hepatol 2010;53:558–567., , ,
- 12Portal hypertension and its complications. Gastroenterology 2008;134:1715–1728., , ,
- 13Portal hypertension: From pathophysiology to clinical practice. Liver Int 2005;25:1079–1090., , , et al.
- 14A canine portal hypertension model induced by intra-portal administration of sephadex microsphere. J Gastroenterol Hepatol 2010;25:778–785., , , et al.
- 15Effect of food on liver circulation in conscious dog. J Vet Med Sci 1995;57:323–326., , , et al.
- 16Indirect and direct determination of portal vein pressure in normal and abnormal dogs and normal cats. Vet Rad 1980;21:246–259.,Direct Link:
- 17Hepatic arterial pressure-flow autoregulation is adenosine mediated. Am J Physiol 1987;252:836–845.,
- 18Estimation of hepatic sinusoid pressure by means of venous catheters and estimation of portal pressure by hepatic vein catheterization. Am J Physiol 1951;165:527–531.,
- 19Effects of hypocapnia on splanchinic circulation and hepatic function in the Beagle. Anesth Analog 1989;69:152–157., , ,
- 20Portal blood flow and oxygen usage in dogs after hemorrhage. Ann Surg 1970;172:284–290., , , et al.
- 21Hepatic outflow resistance, sinusoid pressure, and the vascular waterfall. Am J Physiol 1974;227:513–519.
- 22A modified canine model of portal hypertension with hypersplenism. Scan J Gastroenterol 2009;44:478–485., , , et al.
- 23A novel canine model of esophageal varices with a balloon dilatation constrictor. Dig Dis Sci 2009;54:1449–1455., , , et al.
- 24Effects of different infusion volumes on hemodynamics of portal hypertension in canines after hemorrhagic shock. J Hepatobiliary Pancreat Dis Int 2004;3:571–576., ,
- 25Clinical and experimental study of effect of roandix salviae miltiorrhiza and other blood activating and stasis-eliminating Chinese herbs on hemodynamics of portal hypertension. World J Gastroenterol 1998;4:439–442., , ,
- 26Multiple extrahepatic portosystemic shunts in dogs: 30 cases (1981–1993). J Am Vet Med Assoc 1996;208:1849–1854., , ,
- 27Loss of hepatic venous responsiveness after endotoxin in anesthetized cats. Am J Physiol Heart Circ Physiol 1984;15:H658–H663.,
- 28Localization of intrahepatic portal vascular resistance. Am J Physiol Gastrointest Liver Physiol 1986;14:G375–G381., , ,
- 29Evaluation of hepatic venous balloon occluder to estimate portal pressure. Clin Invest Med 1990;13:247–255., ,
- 30Passive autoregulation of portal venous pressure: Distensible hepatic resistance. Am J Physiol Gastrointest Liver Physiol 1992;26:G702–G708.,
- 31Evaluation of cellophane banding with and without intraoperative attenuation for treatment of congenital extrahepatic portosystemic shunts in dogs. J Am Vet Med Assoc 2006;228:1355–1360., , ,
- 32Clinical outcome of congenital extrahepatic portosystemic shunt attenuation in dogs aged five years and older: 17 cases (1992–2005). J Am Vet Med Assoc 2008;232:722–727.,
- 33A comparison of the ameroid constrictor versus ligation in the surgical management of single extrahepatic portosystemic shunts. J Am Anim Hosp Assoc 2001;37:390–396., , ,
- 34Long-term results of complete and partial ligation of congenital portosystemic shunts in dogs. Vet Surg 1995;24:331–336., ,
- 35Evaluation of ameroid ring constrictors for treatment for single extrahepatic portosystemic shunts in dogs: 168 cases (1995–2001). J Am Vet Med Assoc 2005;226:2020–2030., , , et al.
- 36Surgical management of left-divisional intrahepatic portosystemic shunts: Outcome after partial ligation of, or ameroid ring constrictor placement on, the left hepatic vein in twenty-eight dogs (1995–2005). Vet Surg 2007;36:21–30., , , et al.
- 37Association of portovenographic findings with outcome in dogs receiving surgical treatment for single congenital portosystemic shunts: 45 cases (2000–2004). J Am Vet Med Assoc 2006;229:1122–1129., , , et al.
- 38Congenital extrahepatic portosystimc shunt occlusion in the dog: Gross observation during surgical correction. J Am Vet Med Assoc 1988;24:387–394.,
- 39Association of mesenteric portovenographic findings with outcome in cats receiving surgical treatment for single congenital portosystemic shunts. J Am Vet Med Assoc 2009;234:221–228., , ,
- 40Outcome of ameroid constrictor occlusion of single congenital extrahepatic portosystemic shunts in cats: 12 cases (1993–2000). J Am Vet Med Assoc 2002;220:337–341.,
- 41Evaluation of ameroid ring constrictors for the management of single extrahepatic portosystemic shunts in cats: 23 cases (1996–2001). J Am Vet Med Assoc. 2002;220:1341–1137., , ,
- 42Results of surgical management of feline portosystemic shunts. J Am Anim Hosp Assoc 1990;26:55–62., ,
- 43The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol 2009;6:573–582., , ,
- 44Intrahepatic post-sinusoidal venous obstruction in a dog. J Vet Intern Med 1991;5:317–321., , , et al.
- 45Duplex Doppler ultrasound examination of the portal venous system: An emerging novel technique for the estimation of portal vein pressure. Dig Dis Sci 2010;55:1230–1240., ,
- 46Effects of mechanical and pharmacologic manipulations on portal pressure, central venous pressure, and heart rate in dogs. Am J Vet Res 1991;52:1327–1335., ,
- 47Thrombosis of the portal vien in 11 dogs. Vet Pathol 1993;30:28–35.,
- 48Ascites due to pre-sinusoidal portal hypertension in dogs: A retrospective analysis of 17 cases. Aust Vet J 2008;86:180–186., , ,
- 49Portal hypertension in a dog due to circumscribed fibrosis of the wall of the extrahepatic portal vein. Vet Rec 2002;150:602–605., , ,
- 50Hepatic insufficiency associated with congenital anomalies of the portal vein in dogs. J Am Anim Hosp Assoc 1974;10:463–476., ,
- 51Portal hypertension associated with primary hypoplasia of the portal vein in dogs. Vet Rec 1995;137:424–427., ,
- 52Ultrasound diagnosis of unusual portovenous abnormalities in 2 cats. J Small Anim Prac 2006;47:338–343., , , et al.
- 53Surgical and interventional radiographic treatment of dogs with hepatic arteriovenouse fistulae. Vet Surg 2007;36:199–209., , ,
- 54Ultrasonographic findings associated with congenital hepatic arteriovenous fistula in three dogs. J Am Vet Med Assoc 1988;192:1099–1101., , , et al.
- 55Ascites associated with intrahepatic arteriovenous fistula in a cat. J Am Vet Med Assoc 1976;168:589–591., , ,
- 56Clinical characteristics of idiopathic portal hypertension. World J Gastroenterol 2007;13:1906–1911.,
- 57Hepatoportal fibrosis in three young dogs. Vet Rec 1982;110:575–577.,
- 58Noncirrhotic portal hypertension and nodular regenerative hyperplasia of the liver in dogs with mucopolysaccharidosis type I. Hepatology 1998;28:385–390., , , et al.
- 59Idiopathic noncirrhotic portal hypertension in dogs: 33 cases (1982–1998). J Am Vet Med Assoc 2001;218:392–399., ,
- 60A syndrome resembling idiopathic noncirrhotic portal hypertension in 4 young Doberman Pinschers. J Vet Intern Med 1998;12:147–156., , , et al.
- 61Anomalous portosystemic anastomoses associated with chronic hepatic insufficiency in 6 young dogs. J Am Vet Med Assoc 1975;167:220–228., , , et al.
- 62Portosystemic vascular shunts in a family of American Cocker Spaniels. J Am Anim Hosp Assoc 1988;24:265–272., ,
- 63Idiopathic hepatic fibrosis in 15 dogs. Vet Rec 1993;133:115–228., ,
- 64Congenital hepatic fibrosis in 5 dogs. Vet Pathol 2010;47:102–107., , , et al.
- 65Congenital dilatation of the bile ducts (Caroli's disease) in young dogs. J Vet Intern Med 2003;17:28–32., , ,
- 66Polycystic disease of the kidney and liver in the Cairn Terrier. Vet Pathol 1980;17:436–442.,
- 67Polycystic kidney and liver disease in cats. Vet Q 1998;20:136–139., ,
- 68Acquired portosystemic shunting in 2 cats secondary to congenital hepatic fibrosis. J Vet Intern Med 2005;19:765–767., , ,
- 69Heterobilharzia americana infection in a dog. J Am Vet Med Assoc 2002;220:193–196., , , et al.
- 70Idiopathic hepatitis and cirrhosis in dogs. Vet Clin North Amer Small Anim Pract 2009;39:481–488.
- 71Copper associated liver disease. Vet Clin North Am Small Anim Pract 2009;39:489–512.
- 72Nodular hyperplasia in the liver of the dog: An association with changes in the Ito cell population. Vet Pathol 1985;22:427–438.
- 73Nodular regenerative hyperplasia of the liver with and without portal hypertension: A comparison. Ann Clin Lab Sci 1986;16:155–162., , ,
- 74Hepatic venous outflow obstruction: Three similar syndromes. World J Gastroenterol 2007;13:1912–1927., ,
- 75Induction of hepatic veno-occlusive disease in dogs. Am J Pathol 1987;126:114–125., , , et al.
- 76A canine model for hepatic venoocclusive disease. Transplantation 1992;54:12–16., , ,
- 77Idiopathic hepatic veno-occlusive disease causing Budd-Chiari like syndrome in a cat. J Small Anim Pract 2002;43:411–415., , , ,
- 78Multiple acquired extrahepatic portosystemic shunts secondary to veno-occlusive disease in a young German Shepherd. Can Vet J 2009;50:763–766.
- 79Analyis of prognostic indicators in dogs with pericardial effusion: 49 cases (1985–1996). J Am Vet Med Assoc 1998;212:1276–1280., , ,
- 80Constrictive pericardial disease in the dog. J Am Vet Med Assoc 1984;184:546–553., , ,
- 81A retrospective study of clinical findings, treatment and outcome in 143 dogs with pericardial effusion. J Small Anim Pract 2004;45:546–552., , ,
- 82Budd-Chiari-like syndrome in a dog with a chondrosarcoma of the thoracic wall. J Vet Emerg Crit Care 2007;17:175–178., , , et al.
- 83Budd-Chiari syndrome: Etiology, diagnosis and management. Medicine 1982;61:199–218., , , et al.
- 84Budd-Chiari syndrome in a kitten, caused by membranous obstruction of the caudal vena cava. J Am Anim Hosp Assoc 1995;31:484–491., , ,
- 85Budd-Chiari syndrome in a dog due to liver lobe entrapment within the falciform ligament. J Am Anim Hosp Assoc 2009;45:253–256.
- 86Use of endovascular stents in 3 dogs with Budd-Chiari syndrome. J Am Vet Med Assoc 2009;235:544–550., , ,
- 87Budd-Chiari syndrome in two dogs. J Am Anim Hosp Assoc 1989;25:277–284., , ,
- 88Budd-Chiari syndrome associated with an adrenal phaeochromocytoma in a dog. J Small Anim Pract 2001;442:191–194.,
- 89Budd-Chiari like syndrome caused by a congenital hiatal hernia in a Shar-Pei dog. Vet Rec 2006;159:322–323., , , et al.
- 90Mechanisms of extrahepatic vasodilation in portal hypertension. Gut 2008;57:1300–1314., , ,
- 91Nitric oxide and the hyperdynamic circulation in cirrhosis: Is there a role for selective intestinal decontamination? Clin Sci 2004;107:425–434., ,
- 92Angiogenesis in liver disease. J Hepatol 2009;50:604–620., , , et al.
- 93Pathophysiology of ascites and dilutional hyponatremia: Contemporary use of aquaretic agents. Ann Hepatol 2007;6:214–221., , , et al.
- 94Ascites: Diagnosis and management. Med Clin North Am 2009;93:801–817.,
- 95Chronic bile duct ligation in the dog: Hemodynamic characterization of a portal hypertensive model. Hepatology 1983;3:1002–1007., , ,
- 96A canine model of multiple portosystemic shunting. J Invest Surg 2000;13:45–57., , ,
- 97Management of varices and variceal hemorrhage in cirrhosis. N Eng J Med 2010;362:823–832.,
- 98Esophageal varices due to a probable arteriovenous communication in a dog. J Vet Intern Med 2007;21:1392–1395., , ,
- 99A reproducible canine model of esophageal varices. Gastroenterology 1983;84:573–579., , , et al.
- 100Acquired portal collateral circulation in the dog and cat. Vet Radiol Ultrasound 2010;51:25–33.
- 101Hepatic encephalopathy. Emerg Med Clin North Am 2009;27:401–414.,
- 102Important clinical syndromes associated with liver disease. Vet Clin North Am Small Anim Pract 2009;39:419–437.
- 103Pathogenetic mechanisms of hepatic encephalopathy. Gut 2008;57:1156–1165.,
- 104Hyponatremia in cirrhosis. Pathophysiology, prevalence, prognostic value, treatment. Acta Gastroenterol Belg 2008;71:379–386.
- 105The hepatorenal syndrome. Med Clin North Am 2008;92:813–837.
- 106Management of hepatorenal syndrome. Pharmacol Ther 2008;119:1–6.,
- 107
- 108
- 109Hepatopulmonary syndrome and portopulmonary hypertension. Hepatol Res 2009;39:1020–1022.,
- 110Hepatopulmonary syndrome—a liver-induced lung vascular disorder. N Engl J Med 2008;358:2378–2387.,
- 111Pulmonary complications of cirrhosis. Med Clin North Am 2009;93:871–883.,
- 112Portopulmonary hypertension and right heart failure in patients with cirrhosis. Curr Opin Anaesthesiol 2010;23:145–150.
- 113Severe sepsis in cirrhosis. Hepatology 2009;50:2022–2033., , , et al.
- 114Spontaneous bacterial peritonitis: A severe complication of liver cirrhosis. World J Gastroenterol 2009;15:5505–5510., ,
- 115Primary bacterial peritonitis in dogs and cats: 24 cases (1990–2006). J Am Vet Med Assoc 2009;234:906–913., , ,
- 116Primary bacterial septic peritonitis in cats: 13 cases. J Am Anim Hosp Assoc 2009;45:268–276., ,
- 117Ultrasonographic findings in dogs with hyperammonemia: 90 cases. J Am Vet Med Assoc 2004;224:717–727., , , et al.
- 118The natural history of portal hypertensive gastropathy in patients with liver cirrhosis and mild portal hypertension. Am J Gastroenterol 2004;99:1959–1965., , , et al.
- 119Disruption of the gastric mucosal barrier in dogs. Compend Continuing Educ Pract Vet 2006;28:340–357.,
- 120Gastroduodenal ulceration in dogs. Retrospective study of 43 cases and literature review. J Vet Intern Med 1989;3:238–244.,
- 121Microcytosis and iron status in dogs with surgically induced portosystemic shunts. J Vet Intern Med 1994;8:212–216., , , et al.
- 122Iron status and erythrocyte volume in dogs with congenital portosystemic vascular anomalies. J Vet Intern Med 1997;11:14–19., , , et al.
- 123Coagulation disorders in dogs with hepatic disease. Vet J 2009;185:163–168., , , et al.
- 124Chronic hepatitis in Labrador Retrievers: Clinical presentation and prognostic factors. J Vet Intern Med 2007;21:33–39., , ,
- 125Diagnostic value of fasting plasma ammonia and bile acid concentrations in the identification of portosystemic shunting in dogs. J Vet Intern Med 2006;20:13–19., ,
- 126Evaluation of plasma protein C activity for detection of hepatobiliary disease and portosystemic shunting in dogs. J Am Vet Med Assoc 2006;229:1761–1771., , , et al.
- 127Sensitivity and specificity of fasting ammonia and serum bile acids in the diagnosis of portosystemic shunts in dogs and cats. Vet Clin Pathol 2010;39:57–64., ,
- 128Coagulation in Liver Disease Study Group. Hemostasis and thrombosis in patients with liver disease: The ups and the downs. J Hepatol 2010;53:362–371., , , et al.
- 129Effects of corticosteroid treatment on survival time in dogs with chronic hepatitis: 151 cases (1977–1985). J Am Vet Med Assoc 1988;193:1109–1113., ,
- 130Protein invoked by vitamin K absence and clotting times in clinically ill cats. J Vet Intern Med 2000;14:292–297., , , et al.
- 131Ultrasonographic diagnosis of portosystemic shunting in dogs and cats. Vet Radiol Ultrasound 2004;45:424–437., , ,
- 132Characterization of multiple acquired portosystemic shunts using transplenic portal scintigraphy. Vet Rad Ultrasound 2010;51:466–471., , ,
- 133Estimation of portal blood flow using duplex real-time and pulsed Doppler ultrasound imaging in the dog. Vet Rad 1989;30:222–226., ,
- 134Comparison of three methods for calculating portal blood flow velocity in dogs using duplex-Doppler ultrasonography. Vet Radiol Ultrasound 1994;35:190–194.,
- 135Evaluation of experimentally induced canine hepatic cirrhosis using duplex Doppler ultrasound. Vet Radiol 1990;31:189–194.,
- 136Doppler sonography of portal hypertension. Ultrasound Q 2009;25:3–13., , , et al.
- 137Scintigraphic diagnosis of portosystemic shunts. Vet Clin North Am Small Anim Pract 2009;39:793–810.
- 138Update on hepatobiliary imaging. Vet Clin North Am Small Anim Pract 2009;39:439–467.
- 139Angiography of the hepatic and portal venous system in the dog and cat: An investigative method. Vet Radiol 1980;21:57–77.,
- 140CT diagnosis of portosystemic shunts. Vet Clin North Am Small Anim Pract 2009;39:783–792.
- 141Helical computed tomographic portography in ten normal dogs and ten dogs with a portosystemic shunt. Vet Radiol Ultrasound 2003;44:392–400., , ,
- 142Diagnosis of arterioportal fistulae in four dogs using computed tomographic angiography. Vet Radiol Ultrasound 2005;46:472–477., ,
- 143Magnetic resonance angiography in the management of patients with portal hypertension. Hepatobiliary Pancreat Dis Int 2005;4:239–243., ,
- 144Distal abdominal aortic thrombosis diagnosed by three-dimensional contrast-enhanced magnetic resonance angiography. Vet Radiol Ultrasound 2009;50:370–375., , , et al.
- 145Imaging diagnosis: Azygous continuation of the caudal vena cava with and without portocaval shunting. Vet Radiol Ultrasound 2008;49:573–576.,
- 146Multiphase time-resolved contrast-enhanced portal MRA in normal dogs. Vet Radiol Ultrasound 2009;50:52–57.
- 147Diagnostic comparison of needle and wedge biopsy specimens of the liver in dogs and cats. J Am Vet Med Assoc 2002;220:1483–1490., , , et al.
- 148Thrombosis of the portal vein in a miniature schnauzer. J Small Anim Pract 1999;40:540–543., , ,
- 149Obstructed portal venous flow and portal vein thrombus in a dog. J Am Vet Med Assoc 1989;2004:1449–1451., , ,
- 150Portal vein thrombosis in cats: 6 cases (2001–2006). J Vet Intern Med 2008;22:282–287., , , et al.
- 151Concurrent diseases and condition in dogs with splenic vein thrombosis. J Vet Intern Med 2010;24:1298–1304., , ,
- 152Vascular disorders. In: BurtAD, PortmannBC, FerrellLD, eds. MacSween's Pathology of the Liver, 5th ed. China: Elsevier; 2007:613–648.
- 153Lobular dissecting hepatitis in juvenile and young adult dogs. J Vet Intern Med 1994;8:217–220.,
- 154Lobular dissecting hepatitis in the dog. Vet Pathol 1983;20:179–288., , ,
- 155Chronic hepatitis in three young standard poodles. Zentralbl Veterinarmed A 1991;38:194–297.,
- 156Congenital dilatation of the large and segmental intrahepatic bile ducts (Caroli's disease) in two Golden Retriever littermates. J S AFR Vet Assoc 2006;77:210–214., , ,
- 157Idiopathic hepatic veno-occlusive disease causing Budd-Chiari-like syndrome in a cat. J Small Anim Pract 2002;43:411–415., , , et al.
- 158Population and survival characteristics of cats with hypertrophic cardiomyopathy: 260 cases (1990–1999). J Am Vet Med Assoc 2002;220:202–207., , , et al.
- 159Acquired portosystemic shunting in 2 cats. J Am Anim Hosp Assoc 2002;38:21–27., , ,
- 160Clinical features of inflammatory liver disease in cats: 41 cases (1983–1993). J Am Vet Med Assoc 1999;214:513–516., , , et al.
- 161Diseases of the gallbladder and biliary tree. Vet Clin North Am Small Anim Pract 2009;39:543–598.
- 162Chylous ascites in cats: Nine cases (1978–1993). J Am Vet Med Assoc 1994;205:1161–1164., , ,
- 163Sclerosing cholangitis in a cat. J Am Vet Med Assoc 1983;182:710–712., ,
- 164Three cases of feline sclerosing lymphocytic cholangitis. J Vet Med Sci 1992;54:769–771., , , et al.
- 165Progressive lymphocytic cholangitis in the cat. J Small Anim Pract 1984;25:249–260.,
- 166AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: An update. Hepatology 2009;49:2087–2107.
- 167Effects of lactulose and neomycin on urea metabolism in cirrhotic subjects. Gastroenterology 1982;82:213–217., ,
- 168Current trends in the treatment of hepatic encephalopathy. Ther Clin Risk Manage 2009;5:617–626.,
- 169Pharmacokinetics of L/105, a new rifamycin, in rats and dogs, after oral administration. Chemotherapy 1983;29:1–3.
- 170Nutritional support for dogs and cats with hepatobiliary disease. J Nutr 1998;128:S2733–S2746.
- 171Soy protein isolate versus meat-based low-protein diet for dogs with congenital portosystemic shunts. J Vet Intern Med 2009;23:794–800., , ,
- 172Use of gastroprotectants in treating gastric ulceration in dogs. Compend Continuing Educ Pract Vet 2006;28:358–370.,
- 173Effect of propranolol on hepatic and systemic hemodynamics in dogs with chronic bile duct ligation. Hepatology 1986;6:92–97., ,
- 174Endoscopic demonstration that vasopressin but not propranolol produces gastric mucosal ischemia in dogs with portal hypertension. Gastrointest Endosc 1988;34:310–316., ,
- 175The effect of propranolol on the hyperaemic response of the hepatic artery to portal venous occlusion in the dog. Br J Pharmacol 1989;96:356–362., ,
- 176Carvedilol for portal hypertension in patients with cirrhosis. Hepatology 2010;51:2214–2218.
- 177Effect of octreotide on plasma concentrations of glucose, insulin, glucagon, growth hormone, and cortisol in healthy dogs and dogs with insulinoma. Res Vet Sci 2006;80:25–32., , , et al.
- 178Successful treatment of canine necrolytic migratory erythema (superficial necrolytic dermatitis) due to metastatic glucagonoma with octreotide. Vet Dermatol 2010;21:510–516., , ,
- 179
- 180Nitroglycerin improves the hemodynamic response to vasopressin in portal hypertension. Hepatology 1982;2:757–762., , , et al.
- 181Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: A randomized controlled trial. Gastroenterology 2009;136:1651–1658., , , et al.
- 182Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 2007;46:242–253., , , et al.
- 183Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 2004;126:749–755., , , et al.
- 184Hyperlipidemia in dogs and cats. Vet Med 2007;102:588–599., ,
- 185Use of a combination of prednisolone and rosuvastatin for treatment of a pyogranuloma in a dog. J Am Vet Med Assoc 2010;236:767–769.,
- 186Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005;329:62–65., ,
- 187Renin-angiotensin-aldosteron inhibitors in the reduction of portal pressure: A systematic review and meta-analysis. J Hepatol 2010;53:273–282., , , et al.
- 188Oxygen consumption in the kidney: Effects of nitric oxide synthase isoforms and angiotensin II. Kidney Int 2005;68:723–730., , , et al.
- 189Cardioprotection after angiotensin II type 1 blockade involves angiotensin II type 2 receptor expression and activation of protein kinase C-epsilon in acutely reperfused myocardial infarction in the dog. Effect of UP269-6 and losartan on AT1 and AT2-receptor expression and IP3 receptor and PKCepsilon proteins. J Renin Angiotensin Aldosterone Syst 2000;1:184–195., ,
- 190Endothelin antagonism in portal hypertensive mice: Implications for endothelin receptor-specific signaling in liver disease. Am J Physiol Gastrointest Liver Physiol 2009;297:G27–G33., ,
- 191Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats. Hepatology 2007;46:1208–1217., , , et al.
- 192Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 2009;49:1245–1256., , , et al.
- 193Portopulmonary hypertension: Imatinib as a novel treatment and the Emory experience with this condition. Transplant Proc 2009;41:1969–1971., , , et al.
- 194Tyrosine kinase inhibitors in veterinary medicine. Top Comp Anim Med 2009;24:106–112.


text:
Assignment #131: Wildflowers
The brilliant colors of the wildflower season are as short lived as they are vibrant. If you haven't been out to shoot the wildflowers yet, this Assignment can get you motivated. Think about macro wide-angle and telephoto possibilities. Send in your wildflower photos through midnight on April 16. I'll announce the Assignment Winner on April 17! -Christopher Robinson, Editor
Click here to view our Interactive Gallery Terms & Conditions.
Get 11 Issues of Outdoor Photographer for only $14.97!
That's 77% off the cover price!

subset: commoncrawl


text:
In 100 words or less, tell us about your greatest skating experience. Was it meeting a skater, going to a certain competition, making new friends?
Three lucky people will each win an exquisite Thomas Sabo bracelet. First prize also includes a two-year subscription to IFS; second prize will score you a one-year subscription. The third prizewinner will receive a Thomas Sabo bracelet.
Send your submissions with your full name and address to:
(in either PDF or Word format)
OR, via regular mail to:
The Editor
International Figure Skating
25 Braintree Hill Office Park, Suite 404
Braintree, MA 02184 USA
Contest closes January 31. The winning stories will be published in the March/April issue of IFS.


text:
New inspection guide designed to better justify funding requests.
Assessing risk is key to managing underground assets.
Look for solutions that have the broadest immediate application.
Using technology to boost return on investment.
Drivers compete to see who gets the most miles per gallon.
Three Work Truck Show panelists share what they've learned about clean technologies.
Michigan awards a rehabilitation project based on expectations, not specifications.
Puget Sound begins developing the nation's first "green certification" program.
Long used to rejuvenate roads in the Southwest, asphalt rubber is gaining fans across North America.
A paving material that promises excellent performance, environmental benefits, and reduced cost, warm-mix asphalt (WMA) is generating enthusiasm among transportation managers. Though still largely confined to trial and demonstration projects in the United States, prospects seem favorable for it to...
Copyright ©
2016 Hanley Wood Media, Inc. All rights reserved.


text:
A feeling of great celebration, pride and togetherness was present on Sunday as thousands came to Mosholu Parkway to celebrate the triumphant end of Bronx Week 2014. The festivities began at noon when The 43rd annual Bronx Week parade overflowed Bronx streets with Bronxites as well as non Bronx enthusiasts. Parade participants represented a large portion of the Bronx community from the Military to community organizations like the Bangledeshi Community Council and the Bronx LGBTQ to the NYPD as well as the NYFD, and of course the marching bands and schools of the historic borough.
This, 100 year old part of the city, once condemned as a burning borough, is now definitely a building force to be reckoned with as thousands joyously came together in celebration for all the Bronx Week festivities now rivaling any free outdoor Manhattan event. It was hard to tell officiators from the entertainment at some points, especially when Bronx borough President Ruben Diaz Jr. took the stage to MC; holding his own with world class performers, Rakim, Tony Vega and Elle Varner who came out to the Bedford Park/Norwood sections of the Bronx for the annual Bronx Week closing festival on Mosholu Parkway. Street closures along the entire span of Mosholu Parkway from Van Cortlandt East to Marion and Hull Avenues ensured a traffic free day along the entire span where the many Latin to Italian to Indian to Jamaican food and non food vendors came together.
A true spirit of togetherness was felt as the spirited crowd put their celebrations on hold for a few short moments when President Diaz informed the concerned crowd there was a missing child. The entire audience seemed to silence themselves momentarily as Ruben from the Bronx, led them on the search for the young boy by requesting the crowd to look to their left, right front and back to help locate the juvenile. Moments later a thunderous cheer came over the crowd after President Diaz confirmed the child had been found; further showing what the spirit of togetherness in this borough of strength and determination can do when it concentrates its efforts.
Clearly a good spirit was in full force as one Bronxite summed up the 2014 Bronx Week festivities best by saying, "it is the way that we say we are proud to be Bronxites."


text: Osteopathic Family Relief Fund Page ContentThe AOA's Osteopathic Family Relief Fund (OFRF) assists DOs and osteopathic medical students whose homes and clinics have been damaged in natural disasters. If your family or your practice has been impacted by a disaster, you may be eligible to receive assistance through an OFRF grant. Hurricane Sandy Resources FEMA's Hurricane Sandy resource center lists shelters and explains how survivors can register for assistance. The U.S. Department of Health and Human Services' page on Hurricane Sandy lists open Red Cross shelters and provides disaster-related health information. Disaster Loans The U.S. Small Business Administration (SBA) offers disaster loans to repair or replace damaged real estate, personal property and business assets not covered by insurance or other aid. Here's a look at disaster loans offered by SBA: For small businesses: Disaster loans to cover working capital needs caused by the disaster For homeowners: Up to $200,000 to repair or replace primary homes For homeowners and renters: Up to $40,000 to repair or replace personal property For businesses: Up to $2 million for physical or economic losses. For information on SBA disaster loans, call 1-800-659-2955 (TTY 1-800-977-8339) or visit SBA online. Opportunities for Medical Volunteers The Medical Reserve Corps (MRC) is a national network that engages volunteers to strengthen public health, improve emergency response and build community resilience. Note that there may be a delay in processing your request to volunteer if your MRC is actively providing service. Find your local MRC or visit the New York City MRC page. The Emergency System for Advance Volunteer Registration of Volunteer Health Professionals (ESAR-VHP) verifies the identification and credentials of health professionals who wish to serve in disaster response. This saves valuable time by providing a pool of volunteers whose credentials have already been verified; it also makes it easier to match qualified volunteers with requests for service. Learn more about the program or add yourself to the New York or New Jersey registry. The American Red Cross provides shelter, food, health and mental health services to help families and communities recover from disasters. To help their efforts in New York and New Jersey, contact your local Red Cross chapter or email Mary Casey-Lockyer, disaster health services manager at Red Cross headquarters, at email@example.com. Share This Your browser does not support this functionality. The AOA Is Here For You In the wake of Hurricane Sandy, the OFRF has awarded more than $94,000 in grants to DOs and osteopathic medical students whose homes or practices sustained damage. Please consider a donation to help assist members of the osteopathic family in recovery. Words cannot begin to express my gratitude. Through these finances, I will be able to find a place to live and repurchase some medical books and equipment lost during the hurricane. Taking care of people 'body, mind and spirit' - this is the reason I chose to practice osteopathic medicine. Today, I am proud to be an osteopathic physician. Thank you." - Eniola Teju Ayeni, DO My family is extremely happy and grateful for the grant. Thank you so much to the OFRF committee and all those who have contributed to relief efforts." - Julienne Tropel, DO I cannot thank you enough for your kindness and generosity. This means so much to me. I was actually able to find an apartment and signed the lease agreement this weekend." - Holly Kanavy, DO My sincere thank you to the AOA for the support in the aftermath of Hurricane Sandy." - Lilya Gekhman, DO I am incredibly grateful to the AOA for helping me during this difficult time." - Okyro Collazo, OMS III Contact OFRF For more information or assistance, contact: Verna BronerskyAOA Program email@example.com(800) 621-1773, Ext 8191


text:
The New Orleans Saints on Monday matched the two-year, $4.5 million offer the Atlanta Falcons made to restricted free-agent safety Rafael Bush on Thursday.
An NFL source confirmed the report to The Advocate about a minute before the player did the same with a reporter via an exchange on Twitter. The move then appeared on the league's official transaction wire.
Bush earlier called attention to the situation by tweeting, "I'm still a saint yep."
Bush signed the offer sheet from the NFC South rival Falcons as they were searching for someone to replace Thomas DeCoud, a starting safety for them since 2009 who was released in February. The Saints had until Tuesday to match the offer if they wanted to retain Bush and prevent him from leaving for no compensation.
The Saints in March extended Bush a minimum $1.4 million, one-year contract tender, which gave them the right to match any offers from other teams the safety might consider.
Last year, Bush was credited by the Saints with 45 tackles (29 solo), six pass break-ups, a forced fumble and a fumble recovery over 13 games and six starts.
He also tacked on four special-teams stops as the Saints — whose defense was ranked No. 4 overall and second against the pass — won 12 of their 18 games and made it to the divisional round of the NFC playoffs.
Bush handled an increased workload well early in the season when safeties Malcolm Jenkins and Roman Harper (neither of whom are on the team anymore) were injured.
The analytics website Pro Football Focus gave Bush the 24th-highest grade among NFL safeties in 2013 and rated him as the Saints' best player at the position.
Bush's career began in Atlanta as an undrafted free agent in 2010, and he was on the Falcons practice squad until Denver signed him away in 2011. He played sparingly for the Broncos, who waived him at the end of August 2012. New Orleans soon claimed him.
Bush, who played at South Carolina State, played in all 16 games for the Saints in 2012 and led the special teams with 15 tackles and a fumble recovery. His role on defense initially grew after Jenkins suffered a hamstring injury and landed on injured reserve: Bush had an interception, which he returned 40 yards; forced a fumble; and recovered another fumble.
Bush will stay with a position group that includes Jairus Byrd, who was acquired in March in free agency and whose 22 career interceptions are the most among players at his position since he entered the league in 2009; and Kenny Vaccaro, a 2013 first-round pick who had an excellent rookie season.
There is also safety Marcus Ball, who signed from the Canadian Football League earlier this week. The Saints on Friday reached terms with 12-time Pro Bowl defensive back Champ Bailey, who had been a free agent since Denver released him in March.
It had been speculated that Bailey, who turns 36 in June, might play as a cornerback-safety hybrid.
Other Saints defensive backs are Corey White, Patrick Robinson, Rod Sweeting and Trevin Wade.